

Helen Colhoun

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6388865/publications.pdf](https://exaly.com/author-pdf/6388865/publications.pdf)

Version: 2024-02-01

265
papers

25,175
citations

7528

75
h-index

6766

149
g-index

304
all docs

304
docs citations

304
times ranked

24872
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 685-696.	11.9	3,546
2	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. <i>Lancet</i> , The, 2015, 385, 1397-1405.	11.9	1,165
3	Problems of reporting genetic associations with complex outcomes. <i>Lancet</i> , The, 2003, 361, 865-872.	11.9	1,149
4	Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1302.	6.9	666
5	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet</i> , The, 2019, 393, 407-415.	11.9	551
6	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2014, 64, 485-494.	5.5	524
7	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 37.	6.9	472
8	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011, 43, 117-120.	20.1	396
9	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet</i> , The, 2018, 392, 1311-1320.	11.9	387
10	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 1186-1194.	2.2	356
11	Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2009, 52, 1755-1765.	6.4	353
12	Socio-economic status and blood pressure: an overview analysis. <i>Journal of Human Hypertension</i> , 1998, 12, 91-110.	2.2	342
13	Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1535-1545.	5.5	308
14	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015, 169, 906-915.e13.	3.0	305
15	Blood pressure screening, management and control in England. <i>Journal of Hypertension</i> , 1998, 16, 747-752.	0.5	278
16	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. <i>PLoS Medicine</i> , 2012, 9, e1001321.	8.2	278
17	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ</i> , The, 2020, 371, m3582.	7.5	267
18	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 82-93.	11.1	262

#	ARTICLE	IF	CITATIONS
19	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 597-609.	11.1	260
20	Do men develop type 2 diabetes at lower body mass indices than women?. <i>Diabetologia</i> , 2011, 54, 3003-3006.	6.4	243
21	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014, 176, 55-61.	1.6	233
22	Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). <i>American Journal of Kidney Diseases</i> , 2009, 54, 810-819.	1.9	232
23	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014, 5, 5068.	12.8	223
24	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. <i>PLoS Genetics</i> , 2012, 8, e1002921.	3.3	221
25	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.1	221
26	All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. <i>Diabetologia</i> , 2006, 49, 660-666.	6.4	199
27	Biomarkers of diabetic kidney disease. <i>Diabetologia</i> , 2018, 61, 996-1011.	6.4	189
28	The use of metformin in type 1 diabetes: a systematic review of efficacy. <i>Diabetologia</i> , 2010, 53, 809-820.	6.4	182
29	Common Nonsynonymous Substitutions in SLC11B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 210-216.	4.8	180
30	Insulin resistance in type 1 diabetes: what is "double diabetes"™ and what are the risks?. <i>Diabetologia</i> , 2013, 56, 1462-1470.	6.4	179
31	Mortality in people with Type 2 diabetes in the UK. <i>Diabetic Medicine</i> , 2006, 23, 516-521.	2.5	178
32	Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. <i>PLoS Genetics</i> , 2012, 8, e1002584.	3.3	171
33	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. <i>Circulation</i> , 2013, 128, 1504-1512.	6.2	170
34	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. <i>Atherosclerosis</i> , 2016, 244, 138-146.	0.8	167
35	Design and baseline characteristics of participants in the RESEARCHING cardiovascular events with a Weekly Insulincretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 42-49.	4.5	162
36	Insight into the nature of the CRP "coronary event association using Mendelian randomization. <i>International Journal of Epidemiology</i> , 2006, 35, 922-931.	2.0	159

#	ARTICLE	IF	CITATIONS
37	Effect of Vaccination on Transmission of SARS-CoV-2. <i>New England Journal of Medicine</i> , 2021, 385, 1718-1720.	29.6	157
38	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020, 229, 61-69.	3.0	156
39	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. <i>Kidney International</i> , 2004, 65, 1790-1794.	5.3	150
40	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018, 138, 2774-2786.	6.2	148
41	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	0.5	147
42	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	2.2	146
43	Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 2379-2385.	0.9	145
44	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> , 2015, 58, 493-504.	6.4	145
45	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , The, 2020, 19, 582-590.	10.2	144
46	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.9	142
47	Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. <i>Diabetologia</i> , 2012, 55, 2929-2937.	6.4	132
48	Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. <i>Kidney International</i> , 2015, 88, 888-896.	5.3	127
49	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	2.2	126
50	The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2160-2167.	5.5	118
51	Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study From Scotland. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1054-1060.	3.0	112
52	Diabetes and pregnancy: national trends over a 15-year period. <i>Diabetologia</i> , 2018, 61, 1081-1088.	6.4	112
53	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM&NSULIN</scp> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	4.5	111
54	Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function. <i>Circulation</i> , 2003, 108, 678-683.	6.2	107

#	ARTICLE	IF	CITATIONS
55	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	0.5	106
56	Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). <i>Journal of Lipid Research</i> , 2012, 53, 1000-1011.	4.1	104
57	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 481-487.	11.1	104
58	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	9.0	99
59	Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. <i>Science Advances</i> , 2020, 6, eaax0301.	10.7	98
60	Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. <i>Diabetologia</i> , 2006, 49, 2859-2865.	6.4	97
61	Reduced Incidence of Lower-Extremity Amputations in People With Diabetes in Scotland. <i>Diabetes Care</i> , 2012, 35, 2588-2590.	9.0	95
62	Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 201-211.	2.5	92
63	Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1723-1731.	3.9	92
64	Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. <i>Diabetologia</i> , 2012, 55, 2335-2342.	6.4	86
65	The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. <i>Atherosclerosis</i> , 2003, 167, 243-255.	0.8	85
66	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	5.3	85
67	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY 4 randomised trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	4.5	83
68	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 106-114.	11.1	83
69	Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Clinical Chemistry</i> , 2009, 55, 473-480.	3.4	81
70	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 79-87.	9.0	81
71	Paradoxical Lower Serum Triglyceride Levels and Higher Type 2 Diabetes Mellitus Susceptibility in Obese Individuals with the PNPLA3 148M Variant. <i>PLoS ONE</i> , 2012, 7, e39362.	2.5	80
72	Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1814-1820.	5.5	77

#	ARTICLE	IF	CITATIONS
73	A genome-wide association study suggests an association of <i>CFHR23</i> (<i>CFHR23</i>) with diabetic neuropathic pain. <i>European Journal of Pain</i> , 2015, 19, 392-399.	2.8	76
74	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	75
75	Risk factors for renal failure: The WHO multinational study of vascular disease in diabetes. <i>Diabetologia</i> , 2001, 44, S46-S53.	6.4	74
76	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. <i>Diabetologia</i> , 2016, 59, 2106-2113.	6.4	72
77	A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (<i>CFHR23</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 1386-1393.	5.9	70
78	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. <i>Diabetes Care</i> , 2021, 44, 390-398.	9.0	69
79	Blood pressure in women using oral contraceptives. <i>Journal of Hypertension</i> , 1997, 15, 1063-1068.	0.5	68
80	LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes. <i>Diabetes Care</i> , 2014, 37, 1643-1649.	9.0	68
81	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1127-1132.	9.0	66
82	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. <i>Diabetologia</i> , 2013, 56, 1716-1725.	6.4	66
83	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003374.	8.2	65
84	Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. <i>Human Molecular Genetics</i> , 2012, 21, 5329-5343.	3.0	64
85	Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. <i>British Journal of Ophthalmology</i> , 2014, 98, 790-795.	3.9	64
86	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). <i>International Journal of Epidemiology</i> , 2018, 47, 380-381j.	2.0	64
87	Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes. <i>Diabetes</i> , 2002, 51, 3300-3305.	0.9	63
88	Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. <i>Diabetologia</i> , 2008, 51, 1639-1645.	6.4	61
89	Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. <i>Diabetic Medicine</i> , 1999, 16, 41-48.	2.5	60
90	Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. <i>Diabetes</i> , 2019, 68, 441-456.	0.9	60

#	ARTICLE	IF	CITATIONS
91	Factors associated with stillbirth in women with diabetes. <i>Diabetologia</i> , 2019, 62, 1938-1947.	6.4	58
92	Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1363-1371.	6.4	57
93	A genome-wide association study suggests new evidence for an association of the <i>NADPH Oxidase 4 (NOX4)</i> gene with severe diabetic retinopathy in type 2 diabetes. <i>Acta Ophthalmologica</i> , 2018, 96, e811-e819.	1.1	56
94	Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2005, 48, 2482-2485.	6.4	55
95	Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland. <i>Diabetes Care</i> , 2023, 46, 921-928.	9.0	55
96	Serum kidney injury molecule 1 and β 2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. <i>Diabetologia</i> , 2019, 62, 156-168.	6.4	54
97	Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM complications study. <i>Journal de Physique Théorique et Appliquée</i> , 1998, 15, 418-426.	0.8	53
98	The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. <i>Diabetic Medicine</i> , 1999, 16, 35-40.	2.5	53
99	C-Reactive Protein in Type 1 Diabetes and Its Relationship to Coronary Artery Calcification. <i>Diabetes Care</i> , 2002, 25, 1813-1817.	9.0	53
100	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004724.	3.4	53
101	Crown rot of wheat in Australia: <i>Fusarium pseudograminearum</i> taxonomy, population biology and disease management. <i>Australasian Plant Pathology</i> , 2018, 47, 285-299.	1.0	52
102	Characterizing genetic variants for clinical action. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 93-104.	1.8	51
103	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 121.	1.6	50
104	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. <i>Diabetes Care</i> , 2018, 41, 2010-2018.	9.0	50
105	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. <i>Diabetic Medicine</i> , 2019, 36, 718-725.	2.5	50
106	Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. <i>Journal of Lipid Research</i> , 2004, 45, 1069-1076.	4.1	49
107	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019, 17, 165.	5.6	49
108	Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	6.4	48

#	ARTICLE	IF	CITATIONS
109	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 51.	5.6	48
110	Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. <i>Atherosclerosis</i> , 2002, 163, 363-369.	0.8	46
111	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. <i>Diabetologia</i> , 2012, 55, 2938-2945.	6.4	45
112	Multi-criteria decision analysis for tower crane layout planning in high-rise modular integrated construction. <i>Automation in Construction</i> , 2021, 127, 103709.	9.8	45
113	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 177-183.	1.9	44
114	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. <i>Diabetologia</i> , 2013, 56, 1845-1855.	6.4	44
115	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012-2014): a population-based observational study. <i>Diabetologia</i> , 2018, 61, 108-116.	6.4	44
116	Biomarker panels associated with progression of renal disease in type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 1616-1627.	6.4	44
117	Changes in Endothelium-Dependent Vasodilatation and \pm -Adrenergic Responses in Resistance Vessels during the Menstrual Cycle in Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2499-2504.	3.5	43
118	Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker. <i>BMJ: British Medical Journal</i> , 1997, 314, 1164-1164.	5.6	43
119	Efficacy and Safety of Alirocumab as Add-on Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the <sc>ODYSSEY OPTIONS</sc> Studies. <i>Clinical Cardiology</i> , 2014, 37, 597-604.	1.9	42
120	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	2.2	42
121	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. <i>Diabetologia</i> , 2012, 55, 2356-2360.	6.4	41
122	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. <i>Diabetes Care</i> , 2022, 45, 83-91.	9.0	41
123	Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. <i>Journal of Internal Medicine</i> , 2015, 278, 291-302.	6.1	40
124	Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2007, 50, 733-740.	6.4	39
125	After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. <i>Lancet, The</i> , 2005, 366, 1829-1831.	11.9	37
126	Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 31.	1.6	37

#	ARTICLE	IF	CITATIONS
127	Maternal dietary quality, inflammatory potential and childhood adiposity: an individual participant data pooled analysis of seven European cohorts in the ALPHABET consortium. BMC Medicine, 2021, 19, 33.	5.6	37
128	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Archives of Disease in Childhood, 2021, 106, 1212-1217.	2.7	36
129	Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia, 2016, 59, 299-306.	6.4	35
130	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	6.4	35
131	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 2020, 63, 788-798.	6.4	35
132	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology, 2021, 20, 194.	6.8	35
133	Genome-Wide Association Study of Peripheral Artery Disease. Circulation Genomic and Precision Medicine, 2021, 14, e002862.	3.7	35
134	Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the Health Survey for England. Social Science and Medicine, 1998, 47, 1773-1780.	4.0	34
135	Common Variants in Mendelian Kidney Disease Genes and Their Association with Renal Function. Journal of the American Society of Nephrology: JASN, 2013, 24, 2105-2117.	0.5	34
136	Metformin in adults with type 1 diabetes: <sc>D</sc>esign and methods of <sc>REducing</sc> with <sc>MetfOrmin V</sc>ascular <sc>A</sc>iverse <sc>L</sc>esions (<sc>REMOVAL</sc>): <sc>A</sc>n international multicentre trial. Diabetes, Obesity and Metabolism, 2017, 19, 509-516.	4.5	34
137	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. Diabetologia, 2002, 45, 1362-1371.	6.4	33
138	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. Diabetes Care, 2011, 34, 1992-1997.	9.0	32
139	A genome-wide association study suggests that <i>MAPK14</i> is associated with diabetic foot ulcers. British Journal of Dermatology, 2017, 177, 1664-1670.	1.7	32
140	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.5	31
141	Participatory Research: Its Meaning and Messiness. Beleidsonderzoek Online, 2021, .	0.5	31
142	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. PLoS ONE, 2013, 8, e83292.	2.5	31
143	A noninvasive measure of baroreflex sensitivity without blood pressure measurement. American Heart Journal, 2002, 143, 441-447.	3.0	30
144	Investigation of known estimated glomerular filtration rate loci in patients with Type 2 diabetes. Diabetic Medicine, 2013, 30, 1230-1235.	2.5	30

#	ARTICLE	IF	CITATIONS
145	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. <i>Diabetologia</i> , 2015, 58, 1494-1502.	6.4	30
146	Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. <i>Diabetologia</i> , 2019, 62, 418-425.	6.4	30
147	Distinct Growth Phases in Early Life Associated With the Risk of Type 1 Diabetes: The TEDDY Study. <i>Diabetes Care</i> , 2020, 43, 556-562.	9.0	30
148	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment – systematic review and modelling of progression and cost-effectiveness. <i>Health Technology Assessment</i> , 2014, 18, 1-128.	2.9	30
149	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. <i>Cardiovascular Diabetology</i> , 2017, 16, 114.	6.8	29
150	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. <i>Diabetologia</i> , 2015, 58, 716-725.	6.4	28
151	Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. <i>Diabetes Care</i> , 2018, 41, 2212-2219.	9.0	28
152	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018, 276, 124-130.	0.8	28
153	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 149.	6.8	27
154	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. <i>Diabetes Care</i> , 2020, 43, 734-742.	9.0	27
155	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2001-2011.	6.4	27
156	Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study. <i>BMJ</i> , The, 2021, 374, n2060.	7.5	27
157	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2011, 54, 2000-2008.	6.4	26
158	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). <i>American Journal of Cardiology</i> , 2017, 120, 931-939.	1.5	26
159	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. <i>Journal of Clinical Lipidology</i> , 2017, 11, 986-997.	1.5	25
160	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	6.8	25
161	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020, 63, 636-647.	6.4	25
162	Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. <i>Diabetologia</i> , 2000, 43, 1353-1359.	6.4	24

#	ARTICLE	IF	CITATIONS
163	Antibodies to periodontal pathogens and coronary artery calcification in type 1 diabetic and nondiabetic subjects. <i>Journal of Periodontal Research</i> , 2008, 43, 103-110.	2.7	24
164	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018, 9, 1317-1334.	2.5	24
165	Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 991-1028.	2.5	24
166	Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies. <i>International Journal of Epidemiology</i> , 2018, 47, 617-624.	2.0	23
167	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	6.8	23
168	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	6.4	23
169	Baseline characteristics in the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2004, 21, 901-905.	2.5	22
170	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 484-490.	11.1	21
171	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. <i>Diabetic Medicine</i> , 2018, 35, 99-106.	2.5	20
172	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021, 42, 2565-2573.	2.2	20
173	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 901-907.	9.0	20
174	Development and Validation of a Path Length Calculation for Carotid-Femoral Pulse Wave Velocity Measurement. <i>Hypertension</i> , 2018, 71, 937-945.	4.9	19
175	A Genome-Wide Association Study Provides New Evidence That <i>CACNA1C</i> Gene is Associated With Diabetic Cataract. , 2016, 57, 2246.		18
176	Using Satellite Image Fusion to Evaluate the Impact of Land Use Changes on Ecosystem Services and Their Economic Values. <i>Remote Sensing</i> , 2021, 13, 851.	4.0	18
177	Confirmation needed for genes for hypertension. <i>Lancet, The</i> , 1999, 353, 1200-1201.	11.9	17
178	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. <i>Diabetes and Metabolism</i> , 2017, 43, 453-459.	3.1	17
179	Effects of inaccuracies in arterial path length measurement on differences in MRI and tonometry measured pulse wave velocity. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 118.	1.6	17
180	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020, 19, 199.	6.8	17

#	ARTICLE	IF	CITATIONS
181	Cause-specific mortality in Scottish patients with colorectal cancer with and without type 2 diabetes (2000–2007). <i>Diabetologia</i> , 2013, 56, 1531-1541.	6.4	16
182	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). <i>International Journal of Epidemiology</i> , 2016, 46, dyw152.	2.0	16
183	Automated pathway and reaction prediction facilitates in silico identification of unknown metabolites in human cohort studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1071, 58-67.	2.4	16
184	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1332-1340.	3.2	16
185	The effects of hormone replacement therapy on endothelial function in women with Turner's syndrome. <i>Clinical Endocrinology</i> , 2002, 56, 615-620.	2.5	15
186	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	15
187	Socioeconomic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study. <i>Diabetic Medicine</i> , 2020, 37, 2081-2088.	2.5	15
188	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) <i>Tj ETQqO O O TgBT /Overlock 10</i>	9.0	15
189	Effect of serum sample storage temperature on metabolomic and proteomic biomarkers. <i>Scientific Reports</i> , 2022, 12, 4571.	3.4	15
190	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. <i>BMC Infectious Diseases</i> , 2021, 21, 1275.	2.9	15
191	Cross sectional study of differences in coronary artery calcification by socioeconomic status. <i>BMJ: British Medical Journal</i> , 2000, 321, 1262-1263.	5.6	14
192	Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 171.	1.6	14
193	Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1371-1378.	4.5	14
194	Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin. <i>Diabetologia</i> , 2021, 64, 1725-1736.	6.4	14
195	Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. <i>Nature Medicine</i> , 2024, 30, 2049-2057.	29.5	14
196	Coronary heart disease in women: Why the disproportionate risk?. <i>Current Diabetes Reports</i> , 2006, 6, 22-28.	4.3	13
197	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001–2007. <i>Diabetologia</i> , 2013, 56, 1712-1715.	6.4	13
198	Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imaging. <i>Cardiovascular Diabetology</i> , 2015, 14, 122.	6.8	13

#	ARTICLE	IF	CITATIONS
199	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. <i>Atherosclerosis</i> , 2018, 274, 182-190.	0.8	13
200	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150Åmg doses. <i>Journal of Clinical Lipidology</i> , 2019, 13, 979-988.e10.	1.5	13
201	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022, 65, 159-172.	6.4	13
202	Status report of lipid-lowering trials in diabetes. <i>Current Opinion in Lipidology</i> , 2000, 11, 621-626.	2.8	12
203	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 213-221.	3.4	12
204	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002945.	8.2	12
205	Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. <i>Diabetic Medicine</i> , 2016, 33, 886-895.	2.5	11
206	Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 969-989.	2.5	11
207	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	9.0	11
208	Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. <i>Diabetes Care</i> , 2023, 46, 967-977.	9.0	11
209	Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 1322-1332.	2.9	10
210	Latent class evaluation of the performance of serological tests for exposure to <i>Brucella</i> spp. in cattle, sheep, and goats in Tanzania. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009630.	2.4	10
211	Cohort profile: the Scottish Diabetes Research Network national diabetes cohort - a population-based cohort of people with diabetes in Scotland. <i>BMJ Open</i> , 2022, 12, e063046.	2.1	10
212	Hepatic Metal and Metallothionein Levels in a Potential Sentinel Teleost, <i>Dulesauriga</i> , from a Southeastern Brazilian Estuary. <i>Bulletin of Environmental Contamination and Toxicology</i> , 2019, 103, 538-543.	2.8	9
213	The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. <i>Diabetic Medicine</i> , 2020, 37, 1016-1022.	2.5	9
214	Insulin resistance-associated genetic variants in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107842.	2.4	9
215	Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. <i>Diabetes Research and Clinical Practice</i> , 2023, 204, 110908.	2.8	9
216	Modelling cumulative exposure for inference about drug effects in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1527-1533.	1.9	8

#	ARTICLE	IF	CITATIONS
217	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	6.4	8
218	Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. <i>Glycobiology</i> , 2021, 31, 613-623.	2.8	8
219	Can deep learning on retinal images augment known risk factors for cardiovascular disease prediction in diabetes? A prospective cohort study from the national screening programme in Scotland. <i>International Journal of Medical Informatics</i> , 2023, 175, 105072.	3.5	8
220	The big picture on obesity and insulin resistance**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2002, 40, 944-945.	5.5	7
221	Treatment of lipid disorders in patients with diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 37-45.	0.9	7
222	Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 986-995.	0.9	7
223	Adapting ENABLE for patients with advanced cancer and their family caregivers in Singapore: a qualitative formative evaluation. <i>BMC Palliative Care</i> , 2021, 20, 86.	1.9	7
224	Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. <i>Diabetes Care</i> , 2023, 46, 1524-1530.	9.0	7
225	Whole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease. <i>BMC Medical Imaging</i> , 2016, 16, 18.	2.8	6
226	Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002769.	3.7	6
227	The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information–Diabetes Collaboration. <i>Diabetic Medicine</i> , 2020, 37, 1927-1934.	2.5	6
228	Impact of Cleaner Production and Environmental Management Systems on Sustainability: The Moderating Role of Industry 4.0. <i>IOP Conference Series: Earth and Environmental Science</i> , 2021, 795, 012013.	0.3	6
229	Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. <i>Nature Medicine</i> , 2024, 30, 2058-2066.	29.5	6
230	<i>CKM</i> Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.0	5
231	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1309-1319.	6.4	5
232	Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes. <i>Hypertension</i> , 2021, 78, 40-50.	4.9	5
233	Socioeconomic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a cross-sectional study. <i>Diabetic Medicine</i> , 2020, 37, 1395-1402.	2.5	4
234	Lipid goals in metabolic syndrome and diabetes. <i>Current Atherosclerosis Reports</i> , 2007, 9, 286-295.	4.7	3

#	ARTICLE	IF	CITATIONS
235	Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2018, 9, 1369-1375.	2.5	3
236	Diagnosis of Diabetes in Older Adults. <i>Diabetes Care</i> , 2020, 43, 1373-1374.	9.0	3
237	Reservoir Pressure Integral Is Independently Associated With the Reduction in Renal Function in Older Adults. <i>Hypertension</i> , 2022, 79, 2364-2372.	4.9	3
238	Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. <i>Diabetes Care</i> , 2023, 46, 1046-1051.	9.0	3
239	Incidence of Type 1 Diabetes in Children Has Fallen to Pre-“COVID-19 Pandemic Levels: A Population-Wide Analysis From Scotland. <i>Diabetes Care</i> , 2024, 47, e26-e28.	9.0	3
240	Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. <i>F1000Research</i> , 0, 10, 663.	1.6	2
241	Analysis of leading edge protection application on wind turbine performance through energy and power decomposition approaches. <i>Wind Energy</i> , 2022, 25, 1203-1221.	4.2	2
242	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 412-417.	1.2	2
243	Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. <i>Diabetes</i> , 2024, 73, 823-833.	0.9	2
244	Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. <i>Diabetes Care</i> , 0, , .	9.0	2
245	Taking the V out of genes V environment. <i>Journal of Human Hypertension</i> , 1997, 11, 401-404.	2.2	1
246	The effect of atorvastatin therapy on tumour necrosis factor- α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2011, 11, 288-297.	0.4	1
247	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. <i>Diabetologia</i> , 2014, 57, 260-261.	6.4	1
248	Diabetes in Scotland: a rising tide. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 375-376.	11.1	1
249	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> 2021;44:901-907. <i>Diabetes Care</i> , 2021, 44, e140-e141.	9.0	1
250	A life course approach to diabetes. , 2002, , 121-140.		1
251	1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, , .	0.9	1
252	Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. <i>Diabetologia</i> , 0, , .	6.4	1

#	ARTICLE	IF	CITATIONS
253	A novel common variant with 181 G insertion in the promoter of the gene for phospholipid transfer protein. <i>Atherosclerosis</i> , 2005, 180, 211-213.	0.8	0
254	Eicosapentaenoic acid for prevention of major coronary events. <i>Lancet</i> , The, 2007, 370, 215.	11.9	0
255	Does Treating Hyperlipidaemia with Medication Prevent Complications?. , 2010, , 241-255.		0
256	John Fuller, 21 October 1937–2 July 2020. <i>Diabetologia</i> , 2020, 63, 2251-2252.	6.4	0
257	Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 201.	11.1	0
258	Development of a SARS-CoV-2 virus-like particle that performs as a direct cell entry reporter. <i>Biophysical Journal</i> , 2022, 121, 75a.	0.5	0
259	A peculiar case of palpitations and syncope. <i>Heart Rhythm</i> , 2022, 19, 505-507.	0.8	0
260	Type 2 diabetes exacerbates changes in blood pressure-independent arterial stiffness: cross-sectional and longitudinal evidence from the SUMMIT study. <i>Journal of Applied Physiology</i> , 0, , .	2.6	0
261	Prediction of retinopathy progression using deep learning on retinal images within the Scottish screening programme. <i>British Journal of Ophthalmology</i> , 2024, 108, 833-839.	3.9	0
262	Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment. <i>Ophthalmology Science</i> , 2024, 4, 100494.	2.6	0
263	Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. <i>Diabetologia</i> , 0, , .	6.4	0
264	Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland. <i>Diabetes Care</i> , 0, , .	9.0	0
265	Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. <i>Diabetologia</i> , 0, , .	6.4	0